Synopsis: Baia, Caballero, and colleagues found that NY-ESO-1 is the most frequently expressed cancer/ testis antigen in meningioma tumors, and its expression positively correlates with higher-grade disease and worst prognosis. NY-ESO-1 proteins elicit spontaneous humoral immune responses; the authors propose that NY-ESO-1-based immunotherapy should be explored as a complement to standard therapy for patients with meningioma. 
ABOUT THE COVER
Paul Ehrlich shared the 1908 Nobel Prize with Elie Metchnikoff for their contributions to immunology. Ehrlich described and named mast cells (MC, or, in German mastzellen for "well-fed cells'') in his doctoral thesis in 1878, identifying them in human connective tissue as cells containing abundant intracellular granules that stain purple with certain aniline dyes. Ehrlich noted that MCs were particularly abundant in some human tumors. MCs are long-lived secretory cells derived from hematopoietic precursors that are found in small numbers in the blood but complete their differentiation and maturation in the microenvironments of almost all vascularized tissues. In addition to their known function as effector cells in antigen-induced anaphylaxis and other acute IgE-dependent allergic reactions, MCs have been proposed to have diverse immunomodulatory and several other functions, spanning many aspects of health, host defense, and disease. In tumor biology, individual products of MCs have been shown to have the potential to negatively or positively regulate such processes as the proliferation and survival of tumor cells, tumor-associated angiogenesis and tissue remodeling, metastasis and distant growth of tumor cells, and the ability of tumors to modulate the immune system.
The cover image is a photograph of Paul Ehrlich superimposed on a highpower photomicrograph of a specimen of infiltrating ductal carcinoma of the breast stained by immunohistochemistry to detect tryptase, which identifies mast cells as cells with intensely brown-stained cytoplasm. Steve Galli's research focuses on the development and function of mast cells and basophils (the major effector cells of asthma and anaphylaxis) and the development of new animal models for studying the roles of these cells in health and disease. These models include so-called "mast cell knock-in mice" (i.e., genetically mast cell-deficient mice, bearing mutations affecting c-kit structure or expression, which have been selectively engrafted with wild type or genetically altered mast cells generated in vitro) and, more recently, mice rendered genetically deficient in mast cells and basophils by a mechanism that does not involve mutations affecting c-kit. The Galli group has used these models extensively in efforts to elucidate the roles of mast cells in health and disease.
Dr. Galli was president of the American Society for Investigative Pathology (ASIP; [2005] [2006] and has been elected to the Pluto Club (Association of University Pathologists), the Collegium Internationale Allergologicum (for which he serves as president from 2010-2014), the American Society for Clinical Investigation, the Association of American Physicians, and the Institute of Medicine of the U.S. National Academies. He is also a foreign member of the Accademia Nazionale dei Lincei (National Academy of the Lynxes) in Rome, regarded as the oldest secular scientific society in the Western World. 
